TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.01, expectations were $-0.03.
Tracon Pharmaceuticals Inc. (TCON)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Ikarian Capital Neil Shahrestani | 2,765,530 | $484,244 | 0.04% | |
| 2. | Millennium Management Israel Englander | 191,453 | $33,523 | 0% | |
| 3. | Renaissance Technologies Jim Simons | 98,038 | $17,000 | -28% | 0% |
| 4. | Opaleye Management James A. Silverman | 0 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.75 | 47,000 | Officer, Director | 399,417 | 2023-04-27 | Filing | |
| $0.66 | 3,999 | Officer, Director | 352,417 | 2023-04-26 | Filing | |
| $1.38 | 174,508 | Large Shareholder | 4,324,508 | 2023-03-09 | Filing | |
| $1.52 | 4,800 | Officer, Director | 344,918 | 2023-03-01 | Filing | |
| $1.52 | 200 | Officer, Director | 340,118 | 2023-02-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.26 | 120 | Director | 7,763 | 2022-12-21 | Filing | |
| $1.44 | 1,539 | Large Shareholder | 4,010,000 | 2022-12-06 | Filing | |
| $2.92 | 340,134 | Large Shareholder | 76,048 | 2019-12-09 | Filing | |
| $3.05 | 43,996 | Large Shareholder | 416,182 | 2019-12-05 | Filing | |
| $1.21 | 4,326 | Large Shareholder | 4,601,768 | 2018-11-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 412,271 | $72,189 | 0% | |
| 2. | 262,772 | $46,011 | 0% | |
| 3. | 261,262 | $45,747 | 0% | |
| 4. | 258,844 | $45,324 | 0% | |
| 5. | 208,786 | $36,558 | 0% |
News See All
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q3 2023 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Third Quarter 2023 Earnings Conference Call.
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q2 2023 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the TRACON Pharmaceuticals’ Second Quarter 2023 Earnings Conference Call. At this time, all callers are in a listen-only mode.
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q1 2023 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals First Quarter 2023 Earnings Conference Call. [Operator Instructions].
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2022 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Fourth Quarter and Year Ended 2022 Earnings Conference Call. .
5 Penny Stocks with Upcoming Growth Catalysts
In this article, we discuss the 5 penny stocks with upcoming growth catalysts.
5 Stocks to Buy According to Neil Shahrestani's Ikarian Capital
In this article, we will discuss the 10 stocks to buy according to Neil Shahrestani's Ikarian Capital.
Is TRACON Pharmaceuticals Inc (TCON) A Good Stock To Buy?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns.
Is TRACON Pharmaceuticals (TCON) A Good Stock To Buy Now?
We at Insider Monkey have gone over 817 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of September...
Should You Buy TRACON Pharmaceuticals Inc (TCON)?
In this article we will take a look at whether hedge funds think TRACON Pharmaceuticals Inc (NASDAQ:TCON) is a good investment right now.
Billionaire Hedge Funds
